Sustained release formulation of naltrexone

CAFC
  • US 8,916,195 B2
  • Filed: 06/04/2007
  • Issued: 12/23/2014
  • Est. Priority Date: 06/05/2006
  • Status: Active Grant
First Claim
Patent Images

1. A method of treating overweight or obesity having reduced adverse effects comprising:

  • identifying a subject in need of a treatment for obesity or overweight; and

    orally administering at least daily about 4 mg to about 32 mg of naltrexone and about 90 mg to about 360 mg of bupropion, or pharmaceutically acceptable salts thereof to said subject, wherein the bupropion or pharmaceutically acceptable salt thereof is administered as a sustained-release formulation, wherein the naltrexone or pharmaceutically acceptable salt thereof is administered as a sustained-release formulation having an in vitro naltrexone dissolution profile in a dissolution test of USP Apparatus 2 Paddle Method at 100 rpm in a dissolution medium of water at 37°

    C. of;

    a) between 39% and 70% of naltrexone released in one hour; and

    b) between 62% and 90% of naltrexone released in two hours,whereby at least one adverse effect associated with administration of the same amount of an immediate-release naltrexone formulation and said sustained-release formulation of bupropion or a pharmaceutically acceptable salt thereof is reduced.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×